Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SLC7A1 is a novel candidate for the transport of therapeutics across the blood-brain barrier

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE226607 | GEO | 2023/03/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

BBBomics - Human Blood Brain Barrier Transcriptomics Hub

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-03-17 | E-GEOD-76531 | biostudies-arrayexpress

Brain delivery and efficacy of a lysosomal enzyme using a blood-brain barrier transport vehicle

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-09-16 | GSE139002 | GEO

MiR-155 promotes blood-brain barrier dysfunction in neuroinflammation

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-04-29 | E-GEOD-44694 | biostudies-arrayexpress

A blood-brain barrier transport vehicle improves brain biodistribution of a TREM2 antibody and enhances microglial metabolism via receptor clustering

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-11-23 | GSE200276 | GEO

BBBomics - Human Blood Brain Barrier Transcriptomics Hub

Project description:This SuperSeries is composed of the SubSeries listed below.

2016-03-17 | GSE76531 | GEO

SLC7A1 is a novel candidate for the transport of therapeutics across the blood-brain barrier

Project description:SLC7A1 is a novel candidate for the transport of therapeutics across the blood-brain barrier

| PRJNA940793 | ENA

Development of Novel Therapeutics Targeting the Blood-Brain Barrier: From Barrier to Carrier.

Project description:The blood-brain barrier (BBB) is a highly specialized neurovascular unit, initially described as an intact barrier to prevent toxins, pathogens, and potentially harmful substances from entering the brain. An intact BBB is also critical for the maintenance of normal neuronal function. In cerebral vascular diseases and neurological disorders, the BBB can be disrupted, contributing to disease progression. While restoration of BBB integrity serves as a robust biomarker of better clinical outcomes, the restrictive nature of the intact BBB presents a major hurdle for delivery of therapeutics into the brain. Recent studies show that the BBB is actively engaged in crosstalk between neuronal and the circulatory systems, which defines another important role of the BBB: as an interfacing conduit that mediates communication between two sides of the BBB. This role has been subject to extensive investigation for brain-targeted drug delivery and shows promising results. The dual roles of the BBB make it a unique target for drug development. Here, recent developments and novel strategies to target the BBB for therapeutic purposes are reviewed, from both barrier and carrier perspectives.

| S-EPMC8373165 | biostudies-literature

MiR-155 promotes blood-brain barrier dysfunction in neuroinflammation

Project description:This SuperSeries is composed of the SubSeries listed below.

2014-04-29 | GSE44694 | GEO

NEO100 enables brain delivery of blood‒brain barrier impermeable therapeutics.

Project description:BackgroundIntracarotid injection of mannitol has been applied for decades to support brain entry of therapeutics that otherwise do not effectively cross the blood-brain barrier (BBB). However, the elaborate and high-risk nature of this procedure has kept its use restricted to well-equipped medical centers. We are developing a more straightforward approach to safely open the BBB, based on the intra-arterial (IA) injection of NEO100, a highly purified version of the natural monoterpene perillyl alcohol.MethodsIn vitro barrier permeability with NEO100 was evaluated by transepithelial/transendothelial electrical resistance and antibody diffusion assays. Its mechanism of action was studied by western blot, microarray analysis, and electron microscopy. In mouse models, we performed ultrasound-guided intracardiac administration of NEO100, followed by intravenous application of Evan's blue, methotrexate, checkpoint-inhibitory antibodies, or chimeric antigen receptor (CAR) T cells.ResultsNEO100 opened the BBB in a reversible and nontoxic fashion in vitro and in vivo. It enabled greatly increased brain entry of all tested therapeutics and was well tolerated by animals. Mechanistic studies revealed effects of NEO100 on different BBB transport pathways, along with translocation of tight junction proteins from the membrane to the cytoplasm in brain endothelial cells.ConclusionWe envision that this procedure can be translated to patients in the form of transfemoral arterial catheterization and cannulation to the cerebral arteries, which represents a low-risk procedure commonly used in a variety of clinical settings. Combined with NEO100, it is expected to provide a safe, widely available approach to enhance brain entry of any therapeutic.

| S-EPMC7850137 | biostudies-literature

Copper transport to the brain by the blood-brain barrier and blood-CSF barrier.

Project description:The mechanism of copper (Cu) transport into the brain is unclear. This study evaluated the main species and route of Cu transport into the brain using in situ brain perfusion technique, and assessed the levels of mRNA encoding Cu transporters using real time RT-PCR. Free (64)Cu uptake in rat choroid plexus (CP), where the blood-cerebrospinal fluid barrier (BCB) is primarily located, is about 50 and 1000 times higher than (64)Cu-albumin and (64)Cu-ceruloplasmin uptake, respectively. The unidirectional transport rate constants (K(in)) for Cu in the CP and brain capillaries of the blood-brain barrier (BBB) were 1034 and 319 microl/s/g, respectively, while K(in) in CSF and capillary-depleted parenchyma were much reduced, 0.8 and 112 microl/s/g, respectively. The K(in) in cerebellum was significantly lower than that in hippocampus. The mRNAs encoding Cu transporter-1 (Ctr1) and ATP7A were higher in the CP than those in brain capillaries and parenchyma, whereas ATP7B mRNA was higher in brain capillaries than those in the CP and brain parenchyma. Taken together, these data suggest that the expression of Cu transporters is higher in brain barriers than in brain parenchyma; the Cu transport into the brain is mainly achieved through the BBB as a free Cu ion and the BCB may serve as a main regulatory site of Cu in the CSF.

| S-EPMC2677986 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data